STAT3 and plasma cell myeloma: These results suggest that Atiprimod suppresses STAT3 phosphorylation directly, and that this effect is not dependent on the inhibition of NF-κB. Nevertheless, the ability of Atiprimod to inhibit NF-κB, a proven target in myeloma treatment, suggests that Atiprimod might also inhibit myeloma cells through that mechanism, provided that higher concentrations of this drug are used.